Cargando…
Corrigendum to ‘Long follow-up of symptomatic Multiple Myeloma patients after Covid-19 vaccination (BNT162b2): A single-institution retrospective experience’ Leukemia research reports 18C (100,342)()
Autores principales: | Giuseppe, Mele, Claudia, Romano, Antonella, Miccoli, Angelo, Santoro, Domenico, Pastore |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452217/ https://www.ncbi.nlm.nih.gov/pubmed/36097533 http://dx.doi.org/10.1016/j.lrr.2022.100347 |
Ejemplares similares
-
Long follow-up of symptomatic Multiple Myeloma patients after Covid-19 vaccination (BNT162b2): A single-institution retrospective experience
por: Giuseppe, Mele, et al.
Publicado: (2022) -
P27: HUMORAL RESPONSE RATE POST MRNA COVID19 VACCINATION (BNT162B2) IS HIGLY DEPENDENT TO BONE MARROW PLASMACYTOSIS: LONG FOLLOW-UP OF SYMPTOMATIC MULTIPLE MYELOMA PATIENTS
por: Mele, G, et al.
Publicado: (2022) -
Severe impairment of T-cell responses to BNT162b2 immunization in patients with multiple myeloma
por: Enßle, Julius C., et al.
Publicado: (2022) -
Decline of immune humoral response after BNT162b2 vaccine
por: Ferri, Sonia, et al.
Publicado: (2022) -
Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)